Watch now Icon WATCH NOW: ALPROLIX data in real-world settings

A decade of dedication: our unwavering commitment to you and your patients

10 Years Trusted

Explore our educational resources to learn more about ALPROLIX®

The FACTOR Forum Podcast

The Factor Forum is an engaging podcast series for healthcare professionals that provides peer insights and experiences that have helped them enhance treatment for their patients with hemophilia B. The series dives deep into topics, including treatment approaches, comorbidity management, patient cases, and the benefits of a multidisciplinary care team.

FACTORING IN SHLs AND EHLs FOR HEMOPHILIA B PATIENTS

Looks at the evolution of factor treatment and how EHLs have changed the hemophilia treatment landscape by optimizing care

References

AN APPROACH TO COMPLEX CASES IN HEMOPHILIA B

Explores common comorbidities and how choosing the right treatment regimen can impact patient outcomes and adherence

References

ALPROLIX in clinical and real-world settings

ALPROLIX Clinical Experience: 
A conversation with Dr Amy Shapiro, MD, and Dr Lynn Malec, MD

Protection,* Experience,
 and Dosing:
A Discussion With Dr De Angulo

Access and reimbursement

Billing and
 coding information

The codes listed below are provided for informational purposes only and are not intended to substitute for or influence the independent medical judgment of the prescriber. The codes may not apply to all patients or to all health plans, and additional codes not listed may apply to some patients. The treating physician is solely responsible for diagnosis, coding and determination of the appropriate ICD-10-CM codes that describe the patient’s condition and are supported by the medical record.

The ICD-10-CM and HCPCS codes provided are based on AMA or CMS guidelines. Use of the information below does not guarantee that the payor will provide coverage for ALPROLIX. Because government and other third-party payor coding requirements change periodically, please verify current coding requirements directly with the payor being billed.

ALPROLIX
Instructions for UseDownload icon

This document contains information on how to use ALPROLIX, including reconstitution, pooling, administration, and storage.

ALPROLIX offers a range of financial assistance programs for your patients

Access to these and other services is voluntary, and your patients are not obligated to begin treatment if they contact us. You and your patients make all treatment-related decisions.

Free Trial Plus Program

Patients can receive their first 30-day supply of ALPROLIX generally within 24-48 hours with a valid prescription from their healthcare provider. Sanofi Patient Services will review your patient’s health insurance information for their coverage of ALPROLIX while you and your patient decide if this is the right medication for them to continue taking.

Copay Program

Whether your patient is new to ALPROLIX or already on therapy, ALPROLIX offers a Copay Program to eligible patients that can cover up to $20,000 of copayment, or co-insurance, and out-of-pocket costs associated with their prescription. Best of all, there are no income requirements or caps, so your patient can get started with their treatment right away.

Learn more about Copay Savings for ALPROLIX .

Factor Access Program

Helps your patient access ALPROLIX, even if their insurance coverage is interrupted—for example, they are between jobs or changing insurers.

Sanofi Support Programs Enrollment Form
Sanofi Support Programs Enrollment Form in Spanish (en Español)
Sanofi Support Programs Bilingual Enrollment Form

Copay Program not valid for patients utilizing Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs to pay in part or in full for their prescriptions. Savings may vary depending on patients’ out of pocket costs. Free Trial Plus valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free products dispensed through the Free Trial Plus or Factor Access Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Patients can manage their hemophilia with the help of MicroHealth tracking

Sanofi has joined with MicroHealth in supporting patients and healthcare providers to better manage hemophilia.

hemoapp image

Google Play and the Google Play logo are trademarks of Google LLC.
Apple and the Apple logo are trademarks of Apple Inc. App Store is a service mark of Apple Inc.

Hand holding heart icon

Hemophilia B Advocacy Groups

This listing is provided as a resource only and does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources on this topic may be available and should be investigated. Sanofi does not review or control the content of non-Sanofi websites. These listings do not constitute an endorsement by Sanofi of information provided by any other organizations.

The Coalition for Hemophilia B

National Hemophilia Foundation

Hemophilia Federation of America

World Federation of Hemophilia



IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

  • ALPROLIX is contraindicated in patients who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

WARNINGS AND PRECAUTIONS:

  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with factor replacement therapies, and have been reported with ALPROLIX. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment.
  • Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Patients using ALPROLIX should be monitored for the development of Factor IX inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor IX levels have been achieved and maintained.
  • The use of Factor IX products has been associated with the development of thromboembolic complications.
  • Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.

ADVERSE REACTIONS:

  • The most common adverse reactions (incidence ≥1%) in previously untreated patients were injection site erythema, hypersensitivity, and Factor IX inhibition. The most common adverse reactions (incidence ≥1%) in previously treated patients were headache, oral paresthesia, and obstructive uropathy.

INDICATION:

ALPROLIX is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use
ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

Reference: 1. ALPROLIX [package insert]. Waltham, MA: Bioverativ Therapeutics Inc.